ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2008
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing equipment for the diagnosis and treatment of sleep-disordered breathing and respiratory disorders. The reporting period covers the three months ended September 30, 2008. The company operates manufacturing facilities in Australia, France, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Q1 FY2009 (Sep 30, 2008) | Q1 FY2008 (Sep 30, 2007) |
|---|---|---|
| Net Revenues | $217.9 million | $185.7 million |
| Gross Profit | $127.1 million | $111.8 million |
| Gross Margin | 58.3% | 60.2% |
| Net Income | $28.0 million | $24.1 million |
| Diluted EPS | $0.36 | $0.31 |
| Operating Cash Flow | $67.9 million | $28.1 million |
| Cash and Equivalents | $302.1 million | $251.3 million |
| Total Debt (Current + Long-term) | $145.1 million | Filing text does not provide clear prior period total |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 17% year-over-year, driven by higher unit sales of flow generators, masks, and accessories. Currency movements positively impacted revenue by approximately $5.8 million.
- Margin Compression: Gross margin decreased from 60% to 58%. Management attributed this to a reduction in average selling prices and the appreciation of the Australian dollar against the U.S. dollar, partially offset by manufacturing efficiencies.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 13% due to increased personnel and currency effects. Research and development (R&D) expenses increased 33% to $17.3 million, driven by clinical trials (including the SERVE-HF study) and consulting fees.
- Restructuring: Unlike the prior year which included $2.3 million in restructuring expenses, the current quarter had no restructuring charges.
- Cash Flow Volatility: While operating cash flow more than doubled to $67.9 million, the net cash balance decreased by $19.0 million due to a $52.4 million negative impact from foreign exchange rate changes and increased capital expenditures ($34.5 million).
Guidance, Outlook, and Risks
- Product Pipeline: Management plans to introduce new masks in Europe and the U.S. in the second quarter of fiscal 2009, including the "Swift LT for Her" nasal pillows product.
- Capital Projects: The company is constructing a new corporate headquarters in San Diego. As of September 30, 2008, $53.9 million had been incurred, with an estimated $43.0 million remaining to complete the project by the final quarter of fiscal 2009.
- Liquidity Risk (Auction Rate Securities): The company holds approximately $5.0 million in Aaa-rated auction rate securities. Due to failed auctions caused by global capital market liquidity issues, these were reclassified from current to non-current assets. Management believes the lack of liquidity is temporary and does not anticipate an impact on operations.
- Debt Facilities: On September 30, 2008, the company amended its syndicated facility to add a $50 million Tranche D term loan for general corporate purposes. The company remains in compliance with all debt covenants.
- Legal Proceedings: Ongoing litigation includes a dispute with the University of Sydney regarding intellectual property and a tax audit of a German subsidiary. Management does not expect these to have a material adverse effect.
- Product Recall: The voluntary recall of S8 flow generators initiated in 2007 is nearing completion with negligible additional costs expected and no remaining accrual as of September 30, 2008.
Investor Verification Checklist
- Verify the liquidity status and potential write-down risks associated with the $5.0 million in auction rate securities reclassified as non-current assets.
- Monitor the impact of foreign currency exchange rates (specifically the Australian dollar and Euro) on future gross margins and reported revenues.
- Review the progress and cost overruns of the new San Diego corporate headquarters construction project.
- Assess the outcome of the University of Sydney intellectual property litigation and the German tax authority audit.
- Confirm the utilization of the new $50 million Tranche D debt facility and its impact on leverage ratios.